Abbonarsi

Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: A large single-center experience - 08/08/11

Doi : 10.1016/j.ahj.2008.06.044 
Jonas Eichhöfer, MD, PhD, Eric Horlick, MDCM, Joan Ivanov, PhD, Peter H. Seidelin, MB, John R. Ross, MD, Douglas Ing, MD, Paul Daly, MD, Karen Mackie, RN, Brenda Ridley, BScN, Leonard Schwartz, MD, Alan Barolet, MD, PhD, Vladimír Džavík, MD
Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada 

Reprint requests: Vladimír Džavík, MD, Interventional Cardiology Program, Peter Munk Cardiac Centre, University Health Network, EN 12-224A Toronto General Hospital, 200 Elizabeth St., Toronto, ON, Canada M5G 2C4.

Riassunto

Background

Studies evaluating the efficacy and safety of the transradial approach for percutaneous coronary intervention (PCI) were carried out mainly before the widespread use of stents and glycoprotein (GP) IIb/IIIa inhibitors. We sought to determine the association between the choice of the vascular access site and procedural complications after PCI performed with routine stenting and GP IIb/IIIa inhibition.

Methods

The data source was a prospective registry of 13,499 consecutive cases of PCI at the University Health Network, Toronto, Canada, from April 2000 to September 2006. Logistic regression was used to calculate the probability of selection to the radial access group. Using propensity score methodology, 3,198 patients with femoral access were randomly matched to 3,198 patients with radial access based on clinical, angiographic, and procedural characteristics. Multivariable logistic regression analysis was used to identify the independent predictors of access site–related complications. Major adverse cardiac event was defined as death, myocardial infarction, abrupt vessel closure, or coronary artery bypass surgery.

Results

Use of the transradial approach was associated with fewer vascular access complications (1.5% vs 0.6%, P < .001) and a shorter length of hospital stay. Multivariable analysis revealed transradial access (OR 0.39, 95% CI 0.2-0.7) to be an independent predictor of lower risk, whereas primary PCI (OR 4.36, 95% CI 1.4, 13), recent myocardial infarction (OR 2.0 95% CI 1.2, 3.4), age (per 10 years increase: OR 1.37, 95% CI 1.1-1.7) and female gender (0R 2.78 95% CI 1.7, 4.6) were independent predictors of a higher risk of access site complications.

Conclusions

Use of transradial access for PCI is safe and is independently associated with a reduced rate of in-hospital access site complications and reduced length of hospital stay.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Dr Dzavik was supported in part by the Brompton Funds Professorship in Interventional Cardiology.


© 2008  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 156 - N° 5

P. 864-870 - Novembre 2008 Ritorno al numero
Articolo precedente Articolo precedente
  • Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
  • Shinya Goto, Deepak L. Bhatt, Joachim Röther, Mark Alberts, Michael D. Hill, Yasuo Ikeda, Shinichiro Uchiyama, Ralph D'Agostino, E. Magnus Ohman, Chiau-Suong Liau, Alan T. Hirsch, Jean-Louis Mas, Peter W.F. Wilson, Ramón Corbalán, Franz Aichner, P. Gabriel Steg, on behalf of the REACH Registry Investigators q
| Articolo seguente Articolo seguente
  • Percutaneous coronary implantation of sirolimus-eluting stents in unselected patients and lesions: Clinical results and multiple outcome predictors
  • Giuseppe Sangiorgi, Enrico Romagnoli, Giuseppe Biondi-Zoccai, Massimo Margheri, Corrado Tamburino, Rossella Barbagallo, Elena Falchetti, Guido Vittori, Pierfrancesco Agostoni, John Cosgrave, Antonio Colombo, on behalf of the RECIPE (Real-world Eluting-stent Comparative Italian retrosPective Evaluation) Study Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.